BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 27891632)

  • 1. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
    Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
    Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
    Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
    Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
    Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
    Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
    Hou X; Meng F; Wang J; Sha W; Chiu CT; Chung WC; Gu L; Kudou K; Chong CF; Zhang S
    J Gastroenterol Hepatol; 2022 Jul; 37(7):1275-1283. PubMed ID: 35342997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
    Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
    Hirai A; Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Tominaga K; Tokioka S; Higuchi K
    Dig Dis Sci; 2018 Apr; 63(4):974-981. PubMed ID: 29464587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
    Hamada K; Uedo N; Tonai Y; Arao M; Suzuki S; Iwatsubo T; Kato M; Shichijo S; Yamasaki Y; Matsuura N; Nakahira H; Kanesaka T; Yamamoto S; Akasaka T; Hanaoka N; Takeuchi Y; Higashino K; Ishihara R; Okada H; Iishi H; Fukui K; Shimokawa T
    J Gastroenterol; 2019 Feb; 54(2):122-130. PubMed ID: 29943163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
    Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
    Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
    Kaneko E; Hoshihara Y; Sakaki N; Harasawa S; Ashida K; Asaka M; Asaki S; Nakamura T; Kobayashi K; Kajiyama G; Ogawa N; Yao T; Muto Y; Nakazawa S; Takemoto T
    J Gastroenterol; 2000; 35(11):824-31. PubMed ID: 11085491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
    Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS
    Aliment Pharmacol Ther; 2020 Sep; 52(5):789-797. PubMed ID: 32701188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
    Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
    BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
    Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
    Tan ND; Liu XW; Liu CX; Li SB; Chen HH; Li X; Wu H; Liao AJ; Zhen YB; Shen PZ; Huo LJ; Liu HL; Shi RH; Zhang BQ; Zhang ZY; Wang JN; Zhan Q; Deng H; Shu X; Tuo BG; Wang QZ; Du SY; Qi LZ; Zhang GX; Peng Q; Wang BM; Ye B; Chen MH; Xiao YL
    J Gastroenterol Hepatol; 2022 Nov; 37(11):2060-2066. PubMed ID: 36068945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
    Fujino MA; Morozumi A; Kobayashi K; Ueda F; Suzuki Y; Uchida N; Tachikawa H; Sano S; Ohtsuka H; Yamamoto Y
    J Clin Gastroenterol; 1995; 20 Suppl 2():S44-6. PubMed ID: 7594338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
    Kawai D; Takenaka R; Ishiguro M; Okanoue S; Gotoda T; Kono Y; Takemoto K; Tsugeno H; Fujiki S
    BMC Gastroenterol; 2021 May; 21(1):236. PubMed ID: 34022796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.